Evidence map›Paper›PMID 32445136›Full record

SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2020

Effects of saffron (Crocus sativus L.) on cognitive function. A systematic review of RCTs.

Konstantinos I Avgerinos, Christos Vrysis, Nikolaos Chaitidis, Katerina Kolotsiou, Pavlos G Myserlis, Dimitrios Kapogiannis

Open access · greenAbstract readSystematic Review
In one paragraph

Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Journal of biomedical research · 2024
    Article
  12. Article
  13. Article
  14. Saffron (Nutrients · 2022
    Review
  15. Review
  16. Article
  17. Review
  18. The neuropsychotropic effects ofAvicenna journal of phytomedicine
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Konstantinos I AvgerinosLaboratory of Clinical Investigation, Intramural Research Program, National Institute on Aginga, National Institutes of Health, Baltimore, 3001 S Hanover St, Baltimore, MD, 21225, USA.
Christos Vrysis251 Hellenic Airforce General Hospital, Kanellopoulou 3, 11525, Athens, Greece.
Nikolaos Chaitidis401 General Military Hospital of Athens, Kanellopoulou, 11525, Athens, Greece.
Katerina Kolotsiou251 Hellenic Airforce General Hospital, Kanellopoulou 3, 11525, Athens, Greece.
Pavlos G Myserlis401 General Military Hospital of Athens, Kanellopoulou, 11525, Athens, Greece.
Dimitrios KapogiannisLaboratory of Clinical Investigation, Intramural Research Program, National Institute on Aginga, National Institutes of Health, Baltimore, 3001 S Hanover St, Baltimore, MD, 21225, USA. kapogiannisd@mail.nih.gov.
401 General Military Hospital of Athens · GRHellenic Airforce General Hospital · GRNational Institute on Aging · USNational Institutes of Health · US

Funding

Studies in Dementia and Neurodegenerative DiseasesZIAAG000975 · NIA · NATIONAL INSTITUTE ON AGING · PI KAPOGIANNIS, DIMITRIOS · 2009 to 2025
$31.5M
Intramural NIH HHS Z99 AG999999Intramural NIH HHS ZIA AG000975
6 · The paper itself

Abstract

introductionImprovement of cognitive function may be desirable for healthy individuals and clinically beneficial for those with cognitive impairment such as from Alzheimer's disease (AD) or mild cognitive impairment (MCI). The aim of this systematic review is to investigate the cognitive effects of oral saffron intake, in patients with MCI/AD and/or in non-demented individuals, by following the PRISMA guidelines.

methodsWe performed a literature search on MedLine, Cochrane library, and ClinicalTrials.gov to identify randomized controlled trials (RCTs) investigating the effects of oral saffron administration in patients with MCI/AD and/or in non-demented individuals.

resultsFive studies (enrolling 325 individuals) met our inclusion criteria. Four studies included patients with MCI/AD, and one study included cognitively normal individuals. Saffron was well-tolerated in all groups. Regarding cognitively impaired patients, scores on Alzheimer's Disease Assessment Scale-cognitive subscale or Mini mental state examination were significantly better when saffron was compared with placebo and did not differ significantly when saffron was compared with donepezil or memantine. Saffron effects on functional status were similar with its effects on cognition.

conclusionsSaffron was shown to be equally effective to common symptomatic drugs for MCI/AD and resulted in no difference in the incidence of side effects, when compared with placebo or drugs. The promising results should be seen cautiously, since the evidence was derived from studies with potentially high risk of bias (ROB). RCTs with larger sample sizes and low ROB are required to definitively assess the potential role of saffron as an MCI/AD treatment.

Indexed as

Alzheimer DiseaseCognitive DysfunctionCrocusCognitionDonepezilHumansDonepezilAlzheimer’s diseaseCognitiveCrocus Sativus L.Mild cognitive impairmentSaffronSystematic review

Identifiers

PMID32445136
PMCPMC7484083
OpenAlexW3028568291

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.